Francois Brisebois
Stock Analyst at Oppenheimer
(2.22)
# 2,638
Out of 4,711 analysts
85
Total ratings
38.1%
Success rate
-1.54%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $7.16 | +179.33% | 4 | Dec 17, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $63 → $65 | $52.91 | +22.85% | 6 | Nov 14, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $17.59 | +59.18% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $10.31 | +190.98% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $76.52 | +113.02% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $34.28 | +72.11% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $23.99 | +129.26% | 5 | Sep 3, 2024 | |
| KALA KALA BIO | Reiterates: Outperform | $15 | $5.92 | +153.38% | 2 | Aug 19, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Outperform | $6 | $6.41 | -6.40% | 5 | Aug 16, 2024 | |
| ACHV Achieve Life Sciences | Reiterates: Outperform | $11 | $3.69 | +198.10% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $17.16 | -18.41% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $3.23 | +364.40% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.74 | +427.43% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $28.58 | +127.43% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.88 | +104.92% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.95 | +426.32% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $9.61 | +1,481.69% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.49 | +118.31% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $1.83 | +118.58% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.85 | +6,958.82% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $90 | $0.20 | +46,053.85% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 | $0.45 | +1,011.36% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $3.65 | +132.88% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $8.78 | +25.28% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.26 | +696.46% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $3.97 | +1,159.45% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $3.05 | +106,129.51% | 1 | Feb 4, 2020 |
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $7.16
Upside: +179.33%
Tarsus Pharmaceuticals
Nov 14, 2024
Maintains: Outperform
Price Target: $63 → $65
Current: $52.91
Upside: +22.85%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $17.59
Upside: +59.18%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $10.31
Upside: +190.98%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $76.52
Upside: +113.02%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $34.28
Upside: +72.11%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $23.99
Upside: +129.26%
KALA BIO
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $5.92
Upside: +153.38%
DiaMedica Therapeutics
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.41
Upside: -6.40%
Achieve Life Sciences
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.69
Upside: +198.10%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $17.16
Upside: -18.41%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $3.23
Upside: +364.40%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.74
Upside: +427.43%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $28.58
Upside: +127.43%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.88
Upside: +104.92%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.95
Upside: +426.32%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $9.61
Upside: +1,481.69%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.49
Upside: +118.31%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $1.83
Upside: +118.58%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.85
Upside: +6,958.82%
Feb 6, 2023
Maintains: Outperform
Price Target: $120 → $90
Current: $0.20
Upside: +46,053.85%
Oct 3, 2022
Upgrades: Outperform
Price Target: $5
Current: $0.45
Upside: +1,011.36%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $3.65
Upside: +132.88%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $8.78
Upside: +25.28%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.26
Upside: +696.46%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $3.97
Upside: +1,159.45%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $3.05
Upside: +106,129.51%